 | Up a level |
Dietrich, S., Pircher, A., Andrulis, M. A., Peyrade, F., Wendtner, C. -M, Gaehler, A., Follows, G., Dyer, M., Elter, T., Zeiser, R., Herrmann, M., Herold, M., Dearden, C., Haferlach, T., Hallek, M., Huellein, J., Matutes, E., Duerig, J., von Kalle, C., Glimm, H., Froehling, S., Abdel-Wahab, O., Hutter, B., Steurer, M., Ho, A. and Zenz, T. (2015). Treatment of refractory hairy cell leukemia by BRAF-inhibition. Oncol. Res. Treat., 38. S. 119 - 120. BASEL: KARGER. ISSN 2296-5262
Ritgen, M., Langerak, A., Goede, V., Bahlo, J., Kluth, S., Fischer, K., Steurer, M., Trneny, M., Mulligan, S., Mey, U., Trunzer, K., Humphrey, K., Fingerle-Rowson, G., Stilgenbauer, S., Boettcher, S., Bruggemann, M., Hallek, M., Kneba, M. and van Dongen, J. (2016). QUANTITATIVE MRD IS PROGNOSTIC FOR PROGRESSION-FREE & OVERALL SURVIVAL IN ELDERLY PATIENTS RECEIVING CHLORAMBUCIL ALONE OR WITH OBINUTUZUMAB/RITUXIMAB: A PROSPECTIVE ANALYSIS OF THE GCLLSG CLL11 STUDY. Haematologica, 101. S. 149 - 151. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078